SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5ยข to $5 -- Ignore unavailable to you. Want to Upgrade?


To: GARY P GROBBEL who wrote (20260)4/29/2004 10:16:14 AM
From: rrufff  Respond to of 120411
 
BTNE - 2.95 + 2.0 conservative management rides out rufff times and looks very optimistic. This is from an outfoot that rarely even PR's.

Ballantyne of Omaha Reports First Quarter Net Income Per Diluted Share of $0.06
Business Wire - April 29, 2004 07:00

OMAHA, Neb., Apr 29, 2004 (BUSINESS WIRE) --

- 2004 First Quarter Profits Exceed 2003 Full Year Profit of $0.04
Per Diluted Share

- Q1 Revenues Increase 50% to $11.3 Million

Ballantyne of Omaha, Inc. (OTC BB: BTNE), a manufacturer of motion picture projection and specialty lighting equipment, today reported financial results for the three-month period ended March 31, 2004.

Net revenues for the three months ended March 31, 2004 rose 50% to $11.3 million from $7.5 million in the year-ago period due to a 63% increase in sales of the Company's motion picture projection equipment. Reflecting efficiencies in the manufacturing process, gross profit in the quarter rose 130% to $3.2 million from $1.4 million in the year-ago first quarter. The Company reported net income of $0.9 million, or $0.06 per diluted share, in the first quarter of 2004, compared to a $0.4 million net loss, or a $0.03 loss per diluted share, in the year-ago first quarter. Per share results are based on a weighted average number of shares outstanding of 13,526,233 and 12,608,096 for the first quarters of 2004 and 2003, respectively.

John P. Wilmers, President and Chief Executive Officer of Ballantyne, commented, "As anticipated, we saw increased demand for our motion picture projection equipment during the period, primarily from domestic customers, but also from customers in Asia and Europe. The demand is broad-based, emanating from a wide range of theater owners or equipment distributors and for new equipment and replacement parts alike.

"Our efforts to improve operating efficiencies and right-size the company in advance of this turnaround are paying off, as margins rose significantly over year-ago levels and we delivered our most profitable quarter since 1999, eclipsing the profits we achieved in all of 2003. This performance immediately benefited our balance sheet with cash increasing to $11.5 million and working capital rising to

$21.6 million. At this point in time, we expect favorable industry conditions to continue throughout 2004 and, as such, we expect to continue sustaining current operating performance."

About Ballantyne of Omaha

Ballantyne is a leading U.S. supplier of commercial motion picture and specialty projection equipment utilized by major theater chains and location-based entertainment providers. The Company also manufactures specialty entertainment lighting products used at top arenas, television and motion picture production studios, theme parks and architectural sites around the world.

Except for the historical information in this press release, it includes forward-looking statements that involve risks and uncertainties, including but not limited to, quarterly fluctuations in results; customer demand for the Company's products; the development of new technology for alternate means of motion picture presentation; domestic and international economic conditions; the management of growth; and other risks detailed from time to time in the Company's Securities and Exchange Commission filings. Actual results may differ materially from management's expectations.

Ballantyne of Omaha, Inc. and Subsidiaries
Consolidated Statements of Operations (Unaudited)

Three Months Ended
March 31,

2004 2003
-------------- --------------

Net revenues $ 11,297,412 $ 7,529,510

Cost of revenues 8,139,678 6,154,183
-------------- --------------

Gross profit 3,157,734 1,375,327

Operating expenses:
Selling 744,047 774,134
Administrative 1,031,198 1,131,918
-------------- --------------
Total operating expenses 1,775,245 1,906,052
-------------- --------------

Income (loss) from operations 1,382,489 (530,725)

Other income (expense) (39,951) 139,139
-------------- --------------

Income (loss) before interest and
taxes 1,342,538 (391,586)

Net interest income 1,359 9,771
-------------- --------------

Income (loss) before taxes 1,343,897 (381,815)

Income tax expense 488,902 2,280
-------------- --------------

Net income (loss) $ 854,995 $ (384,095)
============== ==============

Net income (loss) per share:
Basic $ 0.07 $ (0.03)
============== ==============
Diluted $ 0.06 $ (0.03)
============== ==============

Weighted average shares outstanding:
Basic 12,722,261 12,608,096
============== ==============
Diluted 13,526,233 12,608,096
============== ==============

Selected Balance Sheet Items

March 31, 2004 December 31, 2003
(Unaudited)
----------------- -----------------

Cash and cash equivalents $ 11,536,271 $ 8,761,568
Accounts receivable, net 6,304,626 6,698,725
Inventories, net 12,417,567 12,459,852
Current portion of long-term debt 24,663 24,253
Long-term debt 61,984 68,306
Customer deposits 2,512,838 566,434
Accounts payable and accrued
expenses 6,605,383 7,230,850
Total stockholders' equity $ 29,946,604 $ 29,089,089
================ =================

Selected Cash Flow Statement Items (Unaudited):

Three Months Ended
March 31,
2004 2003
----------- ----------
Net income (loss) $ 854,995 $ (384,095)
Depreciation and amortization 290,528 316,138
Net cash provided by operating activities 3,169,164 544,315
Capital expenditures (391,869) (64,023)
Net cash provided by (used in) investing
activities (391,069) 225,977
Net cash used in financing activities (3,392) (3,573)
Net increase in cash & cash equivalents 2,774,703 1,227,861
Cash & cash equivalents at beginning of period 8,761,568 6,276,011
Cash & cash equivalents at end of period $11,536,271 $7,503,872
=========== ==========

SOURCE: Ballantyne of Omaha, Inc.

Ballantyne of Omaha, Inc.
Brad French, 402/453-4444
or
Jaffoni & Collins Incorporated
Stewart Lewack, Joseph Jaffoni, 212/835-8500
btne@jcir.com

Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.

Copyright (C) 2004 Business Wire. All rights reserved.



To: GARY P GROBBEL who wrote (20260)4/29/2004 10:35:39 AM
From: rrufff  Respond to of 120411
 
IMX + .30 Another conservatively run company getting attention on its explosive and drug detection unit. The luxury of having a core business rather than dilution and toxic funding in a developmental stage company is really what makes this company unique. And of course, OUSTANDING SHARES about 7.5 million and float under 4 million.

Implant Sciences Provides Guidance on Third Quarter Revenues; Revenues up 53% over Same Quarter Last Year
Business Wire - April 29, 2004 09:25

WAKEFIELD, Mass., Apr 29, 2004 (BUSINESS WIRE) -- Implant Sciences Corporation (AMEX:"IMX", "IMX.WS") a developer and manufacturer of products for national security, medicine and industry, today provided guidance on its anticipated total revenues for the third quarter ended March 31, 2004. Total revenues for the three months ended March 31, 2004 are expected to be between $2,535,000 and $2,635,000 as compared to $1,693,000 for the comparable prior year period, an average increase of approximately $892,000, or 53%. Total revenues for the nine months ended March 31, 2004 are expected to be between $6,060,000 and $6,160,000 as compared to $4,994,000 for the comparable prior year period, an average increase of $1,116,000 or 22%.

"We are pleased with the revenue growth experienced in our core business units over the most recent quarter that ended on March 31, 2004," stated Dr. Anthony J. Armini, PhD., CEO of Implant Sciences. "Although our investors and shareholders have focused much attention on our continuing progress in bringing the Quantum Sniffer explosives detector to market, we as a management team are also keenly focused on the continued growth of our existing business units. All three existing business units are experiencing growth including radiation therapy devices, contract manufacturing, including semiconductor and orthopedic implant coatings, and government and private contracts and awards."

Dr. Armini further stated, "We are especially gratified at the positive results we are experiencing in the sale of radioactive prostate seeds and semiconductor services resulting from certain key strategies implemented over the past several quarters. Specifically, we are realizing renewed growth in radioactive prostate seeds sales as a direct result of our strategy to utilize a direct sales force rather than selling through a single distributor. Additionally, our decision to invest in new ion implantation equipment for the semiconductor business is also providing us increased service capabilities and increasing our marketing reach. We as a management team will not only focus on bringing new products to market, such as the Quantum Sniffer explosives detector, but we will continue to explore possible acquisitions and strategic alliances that will further our goal of increasing revenue growth for existing businesses and achieving profitability.

About Implant Sciences

Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for national security, medicine, and industry. Under development are portable and bench-top trace element detection devices to identify explosives, narcotics and other toxic materials. The Company has also received government grants from the US Army, Navy and Air Force, and the Transportation Security Administration to adapt the Company's explosive detection technology to a wide number of security requirements.

Using its proprietary ion implantation and thin film coating technologies, Implant Sciences has a sophisticated production line that modifies the surface characteristics of orthopedic joint implants to reduce polyethylene wear, thereby substantially increasing the life of the implants. The company also manufactures and markets radioactive and non-radioactive products for medical use, including radioactive seeds for treating prostate cancer that are distributed throughout the United States by its own direct sales force. In parallel with the production of these seeds, it is also developing additional brachytherapy products for the treatment of breast, eye, and other cancers.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE: Implant Sciences Corporation

Investor contact:
Aurelius Consulting Group
Dave Gentry, 407-644-4256
dave@aurcg.com
www.runonideas.com
or
Implant Sciences Corporation:
David C. Volpe, 508-523-3141
dvolpe@implantsciences.com
www.implantsciences.com
or
Media contact:
The Investor Relations Group
Lisa Lindberg or Janet Vasquez, 212-825-3210

Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.

Copyright (C) 2004 Business Wire. All rights reserved.